

# FASKEN

Fasken Martineau DuMoulin LLP  
Barristers and Solicitors  
Patent and Trade-mark Agents

333 Bay Street, Suite 2400  
P.O. Box 20  
Toronto, Ontario M5H 2T6  
Canada

T +1 416 366 8381  
+1 800 268 8424  
F +1 416 364 7813

fasken.com

June 28, 2022

British Columbia Securities Commission  
Alberta Securities Commission  
Financial and Consumer Affairs Authority of Saskatchewan  
The Manitoba Securities Commission  
Ontario Securities Commission  
Autorité des marchés financiers  
New Brunswick Financial and Consumer Services Commission  
Nova Scotia Securities Commission  
Office of the Superintendent of Securities, Prince Edward Island  
Office of the Superintendent of Securities, Service Newfoundland and Labrador

Dear Sirs/Mesdames:

**Re: Prospectus Supplement to the Final Short Form Base Shelf Prospectus dated May 5, 2021 of Algernon Pharmaceuticals Inc. (the “Issuer”)**

We refer to the prospectus supplement dated June 28, 2022 to the final short form base shelf prospectus dated May 5, 2021 of the Issuer in relation to the offering of units of the Issuer (the “**Prospectus Supplement**”).

We hereby consent to the reference to our firm name in the Introduction and under the headings “Interest of Experts” and “Legal Matters” and to the reference to our firm name and to the use of our opinion under the heading “Eligibility for Investment” in the Prospectus Supplement.

We confirm that we have read the Prospectus Supplement and have no reason to believe that there are any misrepresentations (as defined in the *Securities Act* (Ontario)) in the information contained in the Prospectus Supplement that is derived from our opinion referred to above or that is within our knowledge as a result of the services we performed in connection with such opinions.

This letter is delivered to the addressees pursuant to the requirements of Section 4.2(a)(vii) of National Instrument 44-101.

Yours truly,

***“Fasken Martineau DuMoulin LLP”***